

ASX ANNOUNCEMENT

STATEMENT UNDER S249P OF THE CORPORATIONS ACT

24 NOVEMBER 2023

Melbourne, Australia – In accordance with ASX Listing Rule 3.17.1, Vitura Health Limited (ASX:VIT) (**Vitura** or **Company**) attaches a statement under section 249P of the *Corporations Act 2001* (Cth) in respect of the Company's 2023 Annual General Meeting (**AGM**).

The Company notes that the AGM will be held on at **10.00 am** (Melbourne time) on **Tuesday, 28 November 2023**.

**** ENDS ****

VITURA HEALTH LIMITED

ASX : VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

[VITURA.COM.AU](https://www.vitura.com.au)

BHC'S
CANVIEW

CDA
CLINICS

CORTEXA

Doctors
on Demand
healthcare video consults

cannadoc



About Vitura Health Limited (ASX:VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com

Burleigh Heads Cannabis - operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 260+ product SKUs within Australia from 39 international and domestic medicinal cannabis brands.

- www.canview.com.au

CanView is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The CanView system is based on a medicines wholesaling platform which seamlessly brings together a number of disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are a number of bespoke, internally-generated operating procedures and intellectual property assets, supported by the CanView customer support and infield customer engagement teams. Through the integration of the different elements which together make up CanView, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, CanView provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the CanView platform, without the need to input the patient's details. Prescriptions are then sent directly to the CanView patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the 3,600+ Australian pharmacies with accounts on CanView for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au

The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.

- www.cortexa.com.au

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

- www.cdaclinics.com.au

The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.



- www.cannadoc.com.au

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

Authorised by

Rodney Cocks, Chief Executive Officer and Executive Director

Contact

Vitura Health Limited

Rodney Cocks

Chief Executive Officer and Executive Director

1300 799 491

info@vitura.com.au

Media enquiries

Tim Fogarty

The Civic Partnership

+61 400 179 075


tim.fogarty@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.

Vitura Health Limited Shareholder Statement

Trustee of The Whanau Family Trust



Dear fellow Shareholders.

As the Fourth largest shareholder in Vitura Health, I support the three Director Nominations proposed by Elizabeth Jansen (who is the Trustee for the Stanford Investment Trust and the single largest shareholder).

I co-founded CDA Clinics and CDA Health Ltd in 2018. We decided to focus on patients first and delivering safe and affordable Medicinal Cannabis via CDA Clinics. CDA Clinics had three simple values: Integrity, Honesty and Transparency. We believed if we got these values right then the patients would benefit, as would investors.

I thank all the employees of Vitura for their contribution in making FY23 a profitable and successful year. I would like to say farewell to Dr Simone Scovell (former Independent Non-Executive Director), who sadly and unexpectedly left in September.

I support the addition of Non-Executive Directors to the Board of Vitura. This is consistent with my shareholder statement of 13 September 2022 (to Cronos Australia, as VIT was then known).

It cannot be disputed that both Shane Tanner and Ben Jansen have been instrumental in the creation of the business that we know today as Vitura Health. The presence of 'working' independent directors; directors who intimately understand the industry, and the business, is of vital importance to the future of the company and all its future prospects.

Resolutions 1,4,5, and 6 support increases in remuneration, including by issues of shares.

When CDA Health and Cronos merged in December 2021, I raised the issue at the AGM that the Directors of the proposed merger were getting over 24 million shares and options while the remaining 82 employees were sharing only 2.7 million shares. That was not in my view fair and equitable. I remain of that view including in respect of the proposed resolutions.

Vitura is well-positioned to return long-term growth to shareholders and employees alike, which is strengthened by additional non-executive directors being added to the Board of Vitura.

I implore all shareholders to vote.

Have your say about Shareholder Dilution and Director Remuneration.

Will you vote for more independence and oversight?

Will you vote for a Board that puts the growth of the Company first?

Dr Matua Jansen (ATF The Whanau Family Trust)

24 November 2023